ZNF177 Inhibitors
Chemical inhibitors of ZNF177 can affect the protein by various molecular mechanisms, each involving the disruption of specific signaling pathways and kinases that are essential for its functional regulation. PD168393 and Erlotinib are both inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is a crucial element in the activation of several downstream signaling cascades. By blocking EGFR, these inhibitors can prevent the phosphorylation of ZNF177, assuming that ZNF177's activity is modulated by EGFR-mediated phosphorylation. Similarly, Dasatinib, a broad-spectrum tyrosine kinase inhibitor, can suppress numerous kinases that may phosphorylate ZNF177, thereby affecting its activity.
LY294002 and Wortmannin both target the phosphoinositide 3-kinases (PI3K) pathway, which is known to be upstream of Akt signaling. Inhibition of PI3K by these compounds can lead to a decrease in Akt phosphorylation and, in turn, may lead to reduced activity of ZNF177 if it is regulated by this particular pathway. Furthermore, U0126, a selective inhibitor of mitogen-activated protein kinase kinase (MEK), and SB203580, a specific inhibitor of p38 MAP kinase, both act on different arms of the MAPK pathway. The inhibition of MEK or p38 MAP kinase can diminish the phosphorylation and activity of downstream targets, which may include ZNF177. SP600125, which impedes the c-Jun N-terminal kinase (JNK), operates similarly by potentially decreasing ZNF177 activity if it is under the regulatory influence of JNK signaling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $45.00 $111.00 | 61 | |
PD168393 is an irreversible inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, which can inhibit downstream signaling cascades that ZNF177 may be involved in, leading to a reduction in ZNF177's functional activity by impacting its potential regulation by phosphorylation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K), which are upstream of Akt signaling. Inhibition of PI3K can decrease Akt phosphorylation, potentially reducing ZNF177 activity if its function is regulated by Akt-mediated phosphorylation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. By inhibiting MEK, U0126 may reduce the phosphorylation and activity of downstream proteins, which could include ZNF177 if it is regulated by this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase, which is another MAPK pathway member. Inhibition of p38 MAP kinase could lead to a decrease in ZNF177 activity if ZNF177 is functionally regulated through this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), part of the MAPK pathway. By inhibiting JNK, SP600125 can reduce the functional activity of proteins regulated by JNK signaling, which could include ZNF177. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor like LY294002. By inhibiting PI3K, Wortmannin could decrease the activity of downstream proteins including ZNF177, assuming ZNF177's activity is regulated via PI3K signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor that could inhibit various kinases that phosphorylate ZNF177, thereby inhibiting its activity if ZNF177 is phosphorylated for functional regulation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically inhibits mTOR, which can affect protein synthesis and cellular proliferation. Inhibiting mTOR could decrease the functional activity of ZNF177 if it is regulated by mTOR signaling pathways. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that can change gene expression patterns. Although generally affecting transcription, it could inhibit ZNF177 by altering the acetylation state of proteins that regulate ZNF177's activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. By broadly inhibiting kinase activity, Staurosporine could reduce the phosphorylation and activity of ZNF177 if it is subject to regulation by phosphorylation. | ||||||